Mr. Klausner joined Pappas Ventures in 2005 as a Partner. From 1990 to 2004, he was with Domain Associates, serving as a General Partner from 1997 through 2004. Before becoming a venture capitalist, he spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. Mr. Klausner has previously been a board member at Santarus (IPO in 2004, NASDAQ: SNTS), X-Ceptor (acquired by Exelixis in 2004), and Altea Therapeutics, and he was a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and Cerexa (acquired by Forest Laboratories in 2007). He is currently a board observer at CeNeRx BioPharma. Mr. Klausner earned a BA in Biology from Princeton University and an MBA from Stanford University.